Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer
详细信息 查看全文
- 作者：Agnieszka K. Witkiewicz1 ; 2 ; 3 ; 4 ; awitki@email.arizona.edu" class="auth_mail" title="E-mail the corresponding author ; Uthra Balaji1 ; Cody Eslinger1 ; Elizabeth McMillan5 ; William Conway6 ; Bruce Posner7 ; Gordon B. Mills8 ; Eileen M. O&rsquo ; Reilly9 ; Erik S. Knudsen1 ; 2 ; 4 ; 10 ; eknudsen@email.arizona.edu" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cell Reports
- 出版年：2016
- 出版时间：16 August 2016
- 年：2016
- 卷：16
- 期：7
- 页码：2017-2031
- 全文大小：7500 K
文摘
- ass="listitem" id="list_ulist0010">
- ass="label">•
Only a few genetic events in pancreatic cancer are currently sensitive to therapeutic targeting
- ass="label">•
Patient-derived models can serve as the basis for empirically defined drug sensitivities
- ass="label">•
There are few strong responses to single agents in patient-derived models
- ass="label">•
Drug combination screens reveal diverse therapeutic sensitivities that are patient selective